• Long-term outcomes of emicizumab treatment compared with propensity- score-matched patients receiving traditional IST immediately after diagnosis • 2-year individual patient data from the GTH-AHA-EMI study (n=47, emicizumab weeks 1 to 12, delayed IST after week 12), and the historic GTH-AH 01/2010 study (n=101, immediate IST week 1 to 10 plus on-demand bypassing)